Skip to main content
. Author manuscript; available in PMC: 2015 Oct 1.
Published in final edited form as: J Mol Cell Cardiol. 2014 Aug 9;75:199–205. doi: 10.1016/j.yjmcc.2014.08.001

Figure 4. In vitro study in CFs.

Figure 4

A: Immunocytochemical staining for GC-A, GC-B, NPR-C, and Col I protein expression in CFs at × 100 objective magnification. B: cGMP generation in CFs stimulated by 10−8 and 10−6 M BNP, CNP, or CD-NP. Values are from three experiments and the mean of three samples per treatment. *p<0.05 vs non-treated cells, †p<0.05 vs BNP at the same concentration, ‡p<0.05 vs CNP at the same concentration. C: Col I mRNA expression with or without TGF beta-1 (5 ng/ml) treatment in CFs pretreated with or without 10−8 and 10−6 M BNP, CNP, or CD-NP. Values are from three experiments and the mean of three samples per treatment. *p<0.05 vs non-treated cells, †p<0.05 vs TGF. D: Col I protein expression with or without TGF beta-1 (5 ng/ml) treatment in CFs pretreated with or without 10−6 M CD-NP, determined by Col I ELISA. Values are from three experiments and the mean of three samples per treatment. *p<0.05 vs non-treated cells, †p<0.05 vs TGF.